Efruxifermin details covers drugs, mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details.

Efruxifermin Market Forecast Efruxifermin drug Insight

&ldquo;Efruxifermin Market Size, Forecast, and Emerging Insight &ndash; 2032&rdquo; report provides comprehensive insights about Efruxifermin for Liver fibrosis in the 7MM. A detailed picture of the Efruxifermin for Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019&ndash;2032 is provided in this report along with a detailed description of the Efruxifermin for Liver fibrosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Efruxifermin market forecast, analysis for Liver fibrosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Liver fibrosis.
<h2>Drug Summary</h2>
Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The FDA and European Medicines Agency, or EMA, have respectively granted a Fast Track designation and a Priority Medicines, or PRIME, the designation for EFX for the treatment of NASH. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH.
EFX is currently being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the HARMONY study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Following readout of the Phase IIb SYMMETRY trial, and subsequent interactions with the FDA, Akero expects to finalize the design of the third Phase III clinical trial within the SYNCHRONY program.
&nbsp;
<h3>Scope of the Report</h3>
The report provides insights into:
<ul>
<li>A comprehensive product overview including the Efruxifermin description, mechanism of action, dosage and administration, research and development activities in Liver fibrosis.</li>
<li>Elaborated details on Efruxifermin regulatory milestones and other development activities have been provided in this report.</li>
<li>The report also highlights the Efruxifermin research and development activity in Liver fibrosis in detail across the United States, Europe and Japan.</li>
<li>The report also covers the patents information with expiry timeline around Efruxifermin.</li>
<li>The report contains forecasted sales of Efruxifermin for Liver fibrosis till 2032.</li>
<li>Comprehensive coverage of the late-stage emerging therapies for Liver fibrosis.</li>
<li>The report also features the SWOT analysis with analyst views for Efruxifermin in Liver fibrosis.</li>
</ul>
&nbsp;
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight&rsquo;s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
&nbsp;
<h3>Efruxifermin Analytical Perspective by DelveInsight</h3>
&nbsp;
In-depth Efruxifermin Market Assessment
This report provides a detailed market assessment of Efruxifermin in Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
&nbsp;
Efruxifermin Clinical Assessment
The report provides the clinical trials information of Efruxifermin in Liver fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.
&nbsp;
Report Highlights
<ul>
<li>In the coming years, the market scenario for Liver fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.</li>
<li>The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Efruxifermin dominance.</li>
<li>Other emerging products for Liver fibrosis are expected to give tough market competition to Efruxifermin and launch of late-stage emerging therapies in the near future will significantly impact the market.</li>
<li>A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Efruxifermin in Liver fibrosis.</li>
<li>Our in-depth analysis of the forecasted sales data from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Efruxifermin in Liver fibrosis.</li>
</ul>
&nbsp;
Key Questions
<ul>
<li>What is the product type, route of administration and mechanism of action of Efruxifermin?</li>
<li>What is the clinical trial status of the study related to Efruxifermin in Liver fibrosis and study completion date?</li>
<li>What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Efruxifermin development?</li>
<li>What are the key designations that have been granted to Efruxifermin for Liver fibrosis?</li>
<li>What is the forecasted market scenario of Efruxifermin for Liver fibrosis?</li>
<li>What are the forecasted sales of Efruxifermin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?</li>
<li>What are the other emerging products available in Liver fibrosis and how are they giving competition to Efruxifermin for Liver fibrosis?</li>
<li>Which are the late-stage emerging therapies under development for the treatment of Liver fibrosis?</li>
</ul>

Table of Content
1 Report Introduction
2 Efruxifermin Overview
2.1 Product Detail
2.2 Clinical Development
2.2.1 Clinical Studies
2.2.2 Clinical Trials Information
2.3 Other Developmental Activities
2.4 Product Profile
3 Competitive Landscape (Late-stage Emerging Therapies) *
4 Efruxifermin Market Assessment
4.1 Market Outlook of Efruxifermin in Liver fibrosis
4.2 7MM Analysis
4.2.1 Market Size of Efruxifermin in the 7MM for Liver fibrosis
4.3 Country-wise Market Analysis
4.3.1 Market Size of Efruxifermin in the United States for Liver fibrosis
4.3.2 Market Size of Efruxifermin in Germany for Liver fibrosis
4.3.3 Market Size of Efruxifermin in France for Liver fibrosis
4.3.4 Market Size of Efruxifermin in Italy for Liver fibrosis
4.3.5 Market Size of Efruxifermin in Spain for Liver fibrosis
4.3.6 Market Size of Efruxifermin in the United Kingdom for Liver fibrosis
4.3.7 Market Size of Efruxifermin in Japan for Liver fibrosis
5 SWOT Analysis
6 Analysts&rsquo; Views
7 Appendix
7.1 Bibliography
7.2 Report Methodology
8 DelveInsight Capabilities
9 Disclaimer
10 About DelveInsight
11 Report Purchase Options

“Efruxifermin Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Efruxifermin for Liver fibrosis in the 7MM. A detailed picture of the Efruxifermin for Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Efruxifermin for Liver fibrosis.

Efruxifermin Emerging Drug Insight

Efruxifermin Market Size, Forecast, and Emerging Insight – 2032

Efruxifermin Drug Insight and Market Forecast- 2032 report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition.